ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OCGN vs FATE // 10Y YIELD & FRED MACRO BETA

Ocugen Inc. (NASDAQ) VS. Fate Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OCGN 1 — FATE 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCGN VS. FATE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OCGN FATE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -22.65% — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 8.80% -51.20% +60.00 OCGN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 28.3 45.2 -16.93 FATE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $252.4M $260.0M -$7.6M FATE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OCGN REV FATE REV OCGN GROSS % FATE GROSS % OCGN FCF FATE FCF
FY 2025 $4.4M $6.6M — — -$57.1M -$112.0M
FY 2024 $4.1M $13.6M — — -$45.5M -$123.6M
FY 2023 $6.0M $63.5M — — -$62.1M -$132.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCGN // BETA —
FATE // BETA —